Human thyroid C-cells have very few GLP-1 receptors, and large clinical trials have not shown an increased risk compared to placebo
The glyoxalase system in health and disease
Common GLP-1 Agonists Here is a list of some of the most common GLP-1 medications approved by the FDA: For Type 2 Diabetes: Adlyxin (lixisenatide) Ozempic (semaglutide) Rybelsus (semaglutide, oral tablet) Trulicity (dulaglutide) Victoza (liraglutide) Combination medications like Soliqua Vial (lixisenatide and insulin glargine) For Obesity: Saxenda (liraglutide) Wegovy (semaglutide) Zepbound (tirzepatide) Numerous other states are considering adding these medications because of the potential benefits of reducing obesity and the health complications it may prompt
Compounded tirzepatide is what makes this possible, or buying directly from research labs and reconstituting at home
:max_bytes(150000):strip_icc()/Smoothie-King-Launches-GLP-1-Menu-FT-BLOG1024-f58e53e922864e37b5ea2ad4ae7abd2d.jpg)
the expected effect size is small and the onset is slow - Avoid antidepressants in bipolar depression presenting with subtle increased psychomotor tempo, pressured speech and racing thoughts due to the increased risk of switch and potentially rapid cycling - Consider ETC as a viable option for the treatment of bipolar depression resistant to pharmacological treatment - Never treat with antidepressants without a mood stabiliser - If an antidepressant is added, use mainly SSRIs due to their low switch rate - If an antidepressant is used in maintenance treatment, the occurrence of manic/mixed symptoms should be monitored carefully The above recommendation is consistent with current Danish guidelines for the pharmacological treatment of bipolar disorder [42], which recommend lithium, quetiapine and lamotrigine as first-line agents for bipolar I disorder, current depressive episode, in at least 70% of patients, and for bipolar II disorder, current depressive episode, in at least 60%

For investors, this is a meaningful signal